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BACKGROUND
It is unclear whether patients with early-stage Hodgkin’s lymphoma and negative find-
ings on positron-emission tomography (PET) after three cycles of chemotherapy with 
doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) require radiotherapy.
METHODS
Patients with newly diagnosed stage IA or stage IIA Hodgkin’s lymphoma received 
three cycles of ABVD and then underwent PET scanning. Patients with negative 
PET findings were randomly assigned to receive involved-field radiotherapy or no 
further treatment; patients with positive PET findings received a fourth cycle of 
ABVD and radiotherapy. This trial assessing the noninferiority of no further treat-
ment was designed to exclude a difference in the 3-year progression-free survival 
rate of 7 or more percentage points from the assumed 95% progression-free sur-
vival rate in the radiotherapy group.
RESULTS
A total of 602 patients (53.3% male; median age, 34 years) were recruited, and 571 
patients underwent PET scanning. The PET findings were negative in 426 of these 
patients (74.6%), 420 of whom were randomly assigned to a study group (209 to the 
radiotherapy group and 211 to no further therapy). At a median of 60 months of 
follow-up, there had been 8 instances of disease progression in the radiotherapy 
group, and 8 patients had died (3 with disease progression, 1 of whom died from 
Hodgkin’s lymphoma); there had been 20 instances of disease progression in the 
group with no further therapy, and 4 patients had died (2 with disease progression 
and none from Hodgkin’s lymphoma). In the radiotherapy group, 5 of the deaths 
occurred in patients who received no radiotherapy. The 3-year progression-free sur-
vival rate was 94.6% (95% confidence interval [CI], 91.5 to 97.7) in the radiotherapy 
group and 90.8% (95% CI, 86.9 to 94.8) in the group that received no further ther-
apy, with an absolute risk difference of −3.8 percentage points (95% CI, −8.8 to 1.3).
CONCLUSIONS
The results of this study did not show the noninferiority of the strategy of no 
further treatment after chemotherapy with regard to progression-free survival. 
Nevertheless, patients in this study with early-stage Hodgkin’s lymphoma and 
negative PET findings after three cycles of ABVD had a very good prognosis either 
with or without consolidation radiotherapy. (Funded by Leukaemia and Lymphoma 
Research and others; RAPID ClinicalTrials.gov number, NCT00943423.)
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Long-term survival in early-stage Hodgkin’s lymphoma was first made pos-sible by the introduction of the mantle1 and 
inverted Y2 fields of radiotherapy in the 1960s. 
The addition of adjuvant mechlorethamine, vincris-
tine, procarbazine, and prednisone (MOPP)–like 
chemotherapies improved progression-free survival 
rates,3 but these chemotherapies were associated 
with severe emesis,4 gonadal dysfunction,5,6 and in 
rare cases, secondary leukemia.7 Evidence of late 
toxic effects of mantle-field radiotherapy, such as 
hypothyroidism,8 second cancers (especially of the 
breast9 and lung10), and cardiovascular disease,11,12 
also emerged. Thus, it was increasingly apparent 
that cure was bought at a high price and that less 
damaging therapies were required. Studies were 
therefore performed to evaluate fewer cycles of 
less toxic chemotherapy combined with smaller 
fields or doses of radiotherapy13,14; as a result, for 
the treatment of patients with favorable prognos-
tic features,14,15 two cycles of doxorubicin, bleomy-
cin, vinblastine, and dacarbazine (ABVD)16,17 fol-
lowed by 20 Gy of involved-field radiotherapy is 
now commonly used.15
In moving toward the goal of maximizing cure 
while minimizing toxic effects, greater individu-
alization of therapy is appealing. Positron-emission 
tomography (PET) can be used to predict the prog-
nosis in Hodgkin’s lymphoma, with a high nega-
tive predictive value associated with early meta-
bolic response.18-20 Therefore, this technique might 
be useful in guiding a response-adapted approach 
in early-stage Hodgkin’s lymphoma, whereby pa-
tients who have positive PET findings after chemo-
therapy receive radiotherapy but patients with 
negative PET findings undergo no further treat-
ment. The late toxic effects of radiotherapy are 
avoided in patients cured by chemotherapy, and 
overall survival may be improved. Clearly, however, 
a response-adapted strategy leading to treatment 
de-escalation for some patients requires careful 
evaluation. Here, we report the results of a phase 
3 trial to evaluate response-adapted therapy using 
PET in patients with early-stage Hodgkin’s lym-
phoma (Randomised Phase III Trial to Determine 
the Role of FDG–PET Imaging in Clinical Stages 
IA/IIA Hodgkin’s Disease [RAPID]). Our aim was 
to determine whether patients with clinical stage 
IA or stage IIA Hodgkin’s lymphoma (i.e., one 
nodal site [stage IA] or two or more nodal sites on 
the same side of the diaphragm [stage IIA], with 
no night sweats, unexplained fever [temperature, 
≥38°C], or weight loss of ≥10%21) and negative 
PET findings after three cycles of ABVD chemo-
therapy require consolidation radiotherapy to areas 
of previous involvement to delay or prevent disease 
progression.
Me thods
Eligibility
Previously untreated male or female patients 16 to 
75 years of age with histologically confirmed 
classic Hodgkin’s lymphoma of clinical stage IA 
or IIA, as determined by means of clinical history 
and examination and computed tomographic (CT) 
scan of the thorax, abdomen, and pelvis, were 
eligible for trial entry. A baseline PET scan was not 
mandated and in most cases was not performed. 
Patients with mediastinal bulk (maximal medi-
astinal diameter ≥33% of the internal thoracic 
diameter at T5–T6) were not eligible. Written in-
formed consent was obtained from all patients 
before trial entry.
Study Design
This is an ongoing randomized, controlled, non-
inferiority trial to determine whether there is an 
unacceptable increase in the relapse rate among 
patients with negative PET findings who are as-
signed to no further treatment, as compared with 
patients assigned to receive involved-field radio-
therapy. After baseline staging, eligible and con-
senting patients received three cycles of standard 
ABVD chemotherapy.17 A PET scan was then per-
formed during the 2 weeks after day 15 of ABVD 
cycle 3, and images were transmitted to the core 
laboratory at St. Thomas’ Hospital, King’s Col-
lege, London, for central review. Patients with 
negative PET findings were randomly assigned, 
in a 1:1 ratio, to receive 30 Gy of involved-field 
radiotherapy or no further treatment. Block ran-
domization was performed at the Cancer Research 
UK and University College London Cancer Trials 
Centre; no stratification factors were used. Pa-
tients with positive PET findings received a fourth 
cycle of ABVD and involved-field radiotherapy. 
After completion of the assigned treatment, pa-
tients underwent routine clinical evaluation ev-
ery 3 months in year 1, every 4 months in year 2, 
every 6 months in year 3, and annually thereafter. 
A CT scan was obtained at 6, 12, and 24 months, 
but beyond that there were no protocol-mandated 
CT scans.
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Study Oversight
The authors designed the study, and they vouch 
for the accuracy of the data and fidelity to the 
protocol, which is available with the full text of 
this article at NEJM.org. No commercial support 
was provided. No one who is not an author con-
tributed to the writing of the manuscript.
PET Scanning
PET scanning was performed on full-ring PET or 
PET–CT cameras at centers within the United 
Kingdom National Cancer Research Institute PET 
Research Network. As reported elsewhere,22 cen-
ters complied with commonly agreed-on meth-
ods for quality control to ensure that the perfor-
mance of imaging equipment, data transfer, and 
image quality were within an acceptable range 
that was prespecified by the core laboratory. 
Physicists from the core laboratory visited each 
PET center and scanned a standard plastic struc-
ture (“phantom”) to check image quality and quan-
titative accuracy before starting the study.
Before undergoing scanning, patients fasted for 
6 hours, after which 350 to 400 MBq of 18F-fluoro-
deoxyglucose (FDG) was administered intrave-
nously. Scans were acquired 60 minutes later 
from the skull vertex or base of the brain to the 
upper thighs. Images were deidentified and trans-
ferred to the core laboratory for reporting. Two 
experienced reporters independently scored the 
scans with the use of a 5-point scale to evaluate 
the degree of FDG uptake, if present, as well as 
the likelihood of residual disease. Any differences 
in opinion were resolved by consensus. Results 
were faxed to the trials unit, with a score of 1 or 
2 regarded as indicating negative findings and a 
score of 3, 4, or 5 regarded as indicating positive 
findings. A conservative threshold was chosen to 
define negative PET findings, with uptake equiva-
lent to or lower than uptake in the normal me-
diastinal blood pool regarded as indicating nega-
tive findings.23
Statistical Analysis
When this noninferiority trial was initiated in 
2003, it was designed to have a 10-percentage-
point noninferiority margin — that is, to exclude 
a difference in progression-free survival in the 
group receiving no further treatment of 10 or 
more percentage points from the assumed 3-year 
progression-free survival rate of 95% in the radio-
therapy group. However, after a delegate survey 
at the 7th International Symposium on Hodgkin 
Lymphoma in 2007, the noninferiority margin was 
reduced to 7 percentage points. We calculated that 
46 events of progression or death in total would 
be required for the study to have 90% power to 
exclude the 7-percentage-point difference, at a 5% 
significance level, and we estimated that 400 of 
600 registered patients would have to undergo 
randomization for 46 events to occur. Because 
few events were seen in recent follow-up years, the 
independent data monitoring committee agreed 
that the trial could be reported before the target 
of 46 events was reached; initial results were re-
ported at the American Society of Hematology 
meeting in December 2012 (database frozen in 
March 2012), and additional results are being re-
Figure 1. Screening and Randomization.
420 Underwent randomization
602 Patients were screened
182 Were excluded
145 Had positive PET scan
31 Did not have PET scan
11 Withdrew consent
8 Did not complete 3 cycles
of ABVD
5 Were ineligible and were
withdrawn
3 Were unable to have PET 
scan because of technical 
issue with scanner
2 Died
1 Had progressive disease
1 Had unknown reason
6 Had PET scan but did not
undergo randomization
3 Withdrew
2 Were withdrawn by
clinician
1 Had error
209 Were assigned to involved-
field radiotherapy
183 Received intervention
26 Did not receive intervention
20 Declined to participate
5 Died
1 Had pneumonia
211 Were assigned to no further 
treatment
209 Received no further treatment
2 Received radiotherapy
209 Were included in the analysis 211 Were included in the analysis
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ported here (database frozen in February 2014). 
Any additional events will occur after the 3-year 
time point and will not materially change the main 
result.
The Cox proportional-hazards model was used 
to calculate hazard ratios (hereafter referred to as 
rate ratios) and 95% confidence intervals. Survival 
curves were estimated with the use of the Kap-
lan–Meier method. Analysis of the primary end 
point (defined as the time from the date of ran-
domization to first progression, relapse, or death, 
whichever occurred first) was performed on an 
intention-to-treat and per-protocol basis with the 
use of SAS software, version 9.3 (SAS Institute). 
Secondary end points include the incidence of PET 
scan positivity or negativity after three cycles of 
ABVD, overall survival time and cause of death, 
and incidence and type of second cancers.
R esult s
Patients
From October 2003 through August 2010, a total 
of 602 patients were enrolled in the trial at 94 
centers in the United Kingdom. The median age 
was 34 years (range, 16 to 75), 321 patients (53.3%) 
were male, and 200 patients (33.2%) had stage IA 
disease.
PET Scans
After three cycles of ABVD, 571 patients under-
went PET scanning (Fig. 1). Central review of the 
Characteristic Negative PET Findings
Positive PET Findings 
(N = 145)
Radiotherapy 
(N = 209)
No Further 
Treatment 
(N = 211)
Age — yr
Median 34 34 36
Range 16–74 16–75 18–75
Sex — no. (%)
Male 103 (49.3) 107 (50.7) 96 (66.2)
Female 106 (50.7) 104 (49.3) 49 (33.8)
Ann Arbor stage — no. (%)*
IA 69 (33.0) 70 (33.2) 48 (33.1)
IIA 140 (67.0) 141 (66.8) 97 (66.9)
Favorable pretreatment features — no./total no. (%)†
EORTC criteria14 118/184 (64.1) 122/185 (65.9) 85/158 (53.8)
GHSG criteria15,24 114/175 (65.1) 136/184 (73.9) 97/153 (63.4)
No. of nodal sites — no./total no. (%)
1 77/208 (37.0) 71/210 (33.8) 51/145 (35.2)
2 67/208 (32.2) 78/210 (37.1) 44/145 (30.3)
≥3 64/208 (30.8) 61/210 (29.0) 50/145 (34.5)
Nonmediastinal bulk present — no. (%) 2 (1.0) 1 (0.5) 3 (2.1)
*  The Ann Arbor stages indicate one nodal site (stage IA) or two or more nodal sites on the same side of the diaphragm 
(stage IIA) with no B symptoms (i.e., night sweats, unexplained fever [temperature, ≥38°C], or weight loss of ≥10%).21
†  Complete data for the calculation of prognostic scores were unavailable in some cases. Favorable features as defined 
with European Organisation for Research and Treatment of Cancer (EORTC) criteria include stage I or stage II disease 
with none of the following risk factors: large mediastinal mass, age ≥50 years, elevated erythrocyte sedimentation rate 
(ESR) (ESR ≥50 mm per hour in the absence of B symptoms or ≥30 mm per hour in the presence of B symptoms), and 
four or more involved nodal sites. Favorable features as defined with German Hodgkin Study Group (GHSG) criteria in-
clude stage I or stage II disease with none of the following risk factors: large mediastinal mass, extranodal disease, ele-
vated ESR (ESR ≥50 mm per hour in the absence of B symptoms or ≥30 mm per hour in the presence of B symptoms), 
and three or more involved nodal sites.
Table 1. Pretreatment Characteristics of the Patients.
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locally acquired images showed a PET score of 
1 in 301 patients (52.7%), a score of 2 in 125 pa-
tients (21.9%), a score of 3 in 90 patients (15.8%), 
a score of 4 in 32 patients (5.6%), and a score of 
5 in 23 patients (4.0%). Overall, 426 patients 
(74.6%) had negative PET findings (a score of 1 or 
2), and 145 patients (25.4%) had positive PET find-
ings (a score of 3, 4, or 5). Pretreatment charac-
teristics of the patients with negative findings and 
those with positive findings are summarized in 
Table 1.
Randomization of Patients with Negative PET 
Findings
A total of 420 (98.6%) of the 426 patients with 
negative PET findings underwent randomization, 
with 209 patients randomly assigned to the radio-
therapy group and 211 randomly assigned to the 
group with no further therapy. A total of 6 pa-
tients did not undergo randomization, because 
of patient choice in 3 cases, physician choice in 
2 cases, and an error in 1 case. Of the 209 pa-
tients assigned to the radiotherapy group, 26 did 
not receive this treatment: 20 declined after hav-
ing been told the outcome of randomization, 5 had 
died, and 1 had pneumonia.
Outcomes in the Group with Negative PET 
Findings
At a median of 60 months of follow-up after ran-
domization and more than 36 months after the 
last patient underwent randomization, 40 events 
(disease progression or death) had occurred. Over-
all, 380 patients (90.5%) among the 420 who un-
derwent randomization were alive without dis-
ease progression (193 of 209 patients [92.3%] in 
the radiotherapy group and 187 of 211 patients 
[88.6%] in the group with no further therapy). 
There had been 28 episodes of disease progres-
sion (8 of 209 [3.8%] in the radiotherapy group 
and 20 of 211 [9.5%] in the group with no further 
therapy), 5 deaths after disease progression (3 of 
209 [1.4%] in the radiotherapy group and 2 of 211 
[0.9%] in the group with no further therapy), and 
7 deaths without disease progression (5 of 209 
[2.4%] in the radiotherapy group and 2 of 211 
[0.9%] in the group with no further therapy). 
The distributions of events and causes of death are 
summarized in Tables 2 and 3; 1 patient in the 
radiotherapy group died from Hodgkin’s lym-
phoma.
We performed an intention-to-treat analysis 
that included the 420 patients who underwent 
randomization (Fig. 2A). The 3-year progression-
free survival rate was 94.6% (95% confidence in-
terval [CI], 91.5 to 97.7) in the radiotherapy group 
and 90.8% (95% CI, 86.9 to 94.8) in the group with 
no further therapy. The rate ratio for progression-
free survival was 1.57 (95% CI, 0.84 to 2.97) in 
favor of radiotherapy (P = 0.16); the 3-year abso-
lute risk difference was −3.8 percentage points 
(95% CI, −8.8 to 1.3). The 3-year overall survival 
rate was 97.1% (95% CI, 94.8 to 99.4) in the ra-
diotherapy group and 99.0% (95% CI, 97.6 to 100) 
in the group with no further therapy, with a non-
significant rate ratio of 0.51 (95% CI, 0.15 to 1.68) 
in favor of no further therapy (P = 0.27) (Fig. 3).
Subsequently, a per-protocol analysis involv-
ing 392 patients was performed (Fig. 2B). This 
analysis did not include 28 patients from the 
intention-to-treat analysis — 26 from the radio-
therapy group who had not received radiotherapy 
(20 patients had declined this treatment, 5 had 
died, and 1 had pneumonia) and 2 from the 
Event Negative PET Findings
Positive PET Findings 
(N = 145)
Radiotherapy 
(N = 209)
No Further 
Treatment 
(N = 211)
number of patients (percent)
Alive without disease progression 193 (92.3) 187 (88.6) 127 (87.6)
Disease progression only 8 (3.8) 20 (9.5) 10 (6.9)
Died with disease progression 3 (1.4) 2 (0.9) 5 (3.4)
Died without disease progression 5 (2.4) 2 (0.9) 3 (2.1)
Table 2. Events of Disease Progression or Death.
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group with no further therapy who had received 
radiotherapy. On a per-protocol basis, the 3-year 
progression-free survival rate was 97.1% (95% 
CI, 94.7 to 99.6) in the radiotherapy group and 
90.8% (95% CI, 86.8 to 94.7) in the group with 
no further therapy, with a rate ratio of 2.36 (95% 
CI, 1.13 to 4.95) in favor of radiotherapy (P = 0.02).
Second-line treatment is summarized in Ta-
ble S1 in the Supplementary Appendix, available 
at NEJM.org. Among patients in the group with 
negative PET findings who received second-line 
treatment for recurrent Hodgkin’s lymphoma, 
5 of 10 (50.0%) in the radiotherapy group and 
7 of 22 (31.8%) in the group with no further 
therapy received high-dose chemotherapy and sub-
sequently underwent autologous stem-cell trans-
plantation.
Outcomes in the Group with Positive PET 
Findings
At a median of 62 months of follow-up after 
enrollment among all patients who underwent 
randomization and all patients with positive PET 
findings (565 patients in total), 127 of the 145 
patients (87.6%) in the group with positive PET 
findings were alive without disease progression 
(Fig. S1 in the Supplementary Appendix). There 
had been 18 events in this group; 10 events of 
PET Status, Sex, and Age at Registration
Time from End of 
Therapy to Death Cause of Death
Negative PET findings, radiotherapy group
Male, 71 yr* 3 wk Pneumonia
Male, 70 yr*† 4 wk Pneumonitis
Male, 62 yr* 7 wk Cerebral hemorrhage
Female, 73 yr*† 9 wk Pneumonitis
Male, 61 yr*‡ 4 mo Angioimmunoblastic T-cell lymphoma
Male, 28 yr§ 20 mo Myocardial fibrosis and heart failure
Female, 74 yr 54 mo Hodgkin’s lymphoma
Male, 67 yr 60 mo Mycosis fungoides
Negative PET findings, group with 
no further treatment
Female, 75 yr 3 wk Bronchopneumonia
Female, 64 yr 31 mo Small-cell carcinoma of lung
Male, 64 yr 60 mo Diffuse large-B-cell lymphoma
Male, 51 yr 69 mo Mantle-cell lymphoma
Positive PET findings
Female, 60 yr 4 wk Pneumonia
Male, 57 yr 10 mo Pneumonia
Male, 55 yr 14 mo Hodgkin’s lymphoma
Male, 59 yr 19 mo Hodgkin’s lymphoma
Male, 46 yr 24 mo Hodgkin’s lymphoma
Male, 27 yr 25 mo Diffuse large-B-cell lymphoma
Male, 74 yr 28 mo Hodgkin’s lymphoma
Male, 32 yr 64 mo Meningitis
*  Although randomly assigned to the radiotherapy group, this patient did not receive radiotherapy.
†  The pneumonitis in this patient was probably caused by the bleomycin component of ABVD.
‡  After re-review of the histologic data at the time of recurrence, this patient was determined to have had angioimmuno-
blastic T-cell lymphoma at trial entry.
§  This patient had received a field of radiotherapy incorporating the heart.
Table 3. Causes of Death.
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disease progression (6.9% of the patients), 5 deaths 
with disease progression (3.4% of the patients), 
and 3 deaths without disease progression (2.1% of 
the patients) (Table 2). A total of 8 of the 14 pa-
tients (57.1%) in this group who received second-
line treatment underwent transplantation (7 pa-
tients underwent autologous transplantation, and 
1 underwent allogeneic transplantation) (Table S1 
in the Supplementary Appendix).
Discussion
RAPID was designed to determine whether pa-
tients with clinical stage IA or stage IIA Hodgkin’s 
lymphoma and negative PET findings after three 
cycles of ABVD require consolidation radiotherapy. 
If not, the number of patients receiving radiother-
apy could be reduced, and the late toxic effects of 
this therapy could be avoided for patients cured 
by chemotherapy alone. Chemotherapy alone has 
previously been compared with combined chemo-
therapy and radiotherapy in a trial conducted by 
the National Cancer Institute of Canada Clinical 
Trials Group and Eastern Cooperative Oncology 
Group. Initial disease control was superior in the 
group receiving combination therapy,25 but after 
longer follow-up, survival was better among pa-
tients treated with chemotherapy alone.26 That 
study has been criticized for using wide-field ra-
diotherapy, but it highlighted the importance of 
analyzing survival after an appropriate follow-up 
period in studies of curable cancers in which the 
treatment itself may have a negative effect on this 
end point.26,27
In the study-design phase of RAPID, it was 
acknowledged that progression-free survival in the 
group with no further therapy was likely to be 
lower than that in the radiotherapy group because 
the negative predictive value of PET, although high, 
is less than 100%.28 This was judged to be accept-
able, as long as the reduction in disease control 
was not excessive, because of the likely benefits 
in overall survival that would result from a lower 
incidence of second cancers and cardiovascular 
disease in association with exposing fewer pa-
tients to radiation. Whether −7 percentage points 
is an appropriate margin of noninferiority is a 
value judgment, but it represents an attempt to 
balance the effects of treatment on disease con-
trol and late toxic effects.
Our results show that when quality-assured 
PET-image acquisition and central review are used, 
patients with nonbulky stage IA or stage IIA Hodg-
kin’s lymphoma and negative PET findings after 
three cycles of ABVD have an excellent prognosis 
without further treatment (3-year progression-free 
and overall survival rates of 90.8% and 99.0%, re-
spectively). Patients in the radiotherapy group had 
3-year progression-free and overall survival rates 
Figure 2. Kaplan–Meier Plots of Progression-free Survival.
Included are data from patients with negative positron-emission tomogra-
phy (PET) findings who underwent randomization. The intention-to-treat 
analysis included 420 patients, and the per-protocol analysis included 392 
patients.
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of 94.6% and 97.1%, respectively, with nonsignifi-
cant rate ratios for the radiotherapy group as com-
pared with the group receiving no further thera-
py of 1.57 (95% CI, 0.84 to 2.97; P = 0.16) and 0.51 
(95% CI, 0.15 to 1.68; P = 0.27), respectively. It is 
important to note that the lower limit of the 95% 
confidence interval for the absolute risk differ-
ence (−3.8 percentage points; 95% CI, −8.8 to 1.3) 
exceeds the designated noninferiority margin of 
−7 percentage points, with only 40 of the required 
46 events observed despite the fact that it has been 
3 years since the last patient underwent random-
ization.
Of the eight deaths in the radiotherapy group, 
three (due to Hodgkin’s lymphoma, heart failure, 
and second cancer) occurred in patients who had 
actually received radiotherapy. The other five 
deaths in the radiotherapy group occurred in pa-
tients who had been assigned to the radiotherapy 
group but had not received radiotherapy. This in-
cluded one death from T-cell lymphoma in which 
re-review of the patient’s diagnostic biopsy results 
revealed that this condition rather than Hodgkin’s 
lymphoma was present at trial entry (i.e., the pa-
tient was enrolled in error). The remaining four 
deaths were due to pneumonitis (two), pneumo-
nia (one), and cerebral hemorrhage (one), and it 
seems likely that chemotherapy was implicated 
in at least three of these cases. No deaths from 
Hodgkin’s lymphoma have so far been observed 
in the group with negative PET findings who 
were randomly assigned to no further therapy.
The per-protocol analysis showed virtually no 
difference from the intention-to-treat analysis in 
terms of the 3-year progression-free survival rate 
in the group with no further therapy (90.8%; 
95% CI, 86.8 to 94.7), because only 2 patients 
randomly assigned to no further therapy received 
radiotherapy. However, the per-protocol analysis 
showed a greater 3-year progression-free survival 
rate than the intention-to-treat analysis in the ra-
diotherapy group — 97.1% (95% CI, 94.7 to 99.6), 
with a rate ratio of 2.36 (95% CI, 1.13 to 4.95; 
P = 0.02) — because 26 patients did not receive 
the assigned radiotherapy and 6 events occurred 
among those patients.
These results, 3 years after the last patient 
with negative PET findings underwent random-
ization, show that a modest improvement in the 
3-year progression-free survival rate (3.8 percent-
age points in the intention-to-treat analysis and 
6.3 percentage points in the per-protocol analysis) 
can be obtained with the addition of radiotherapy. 
However, this effect is bought at the expense of 
exposing all patients to radiation, most of whom 
will not benefit and some of whom will be 
harmed. In fact, for patients cured with chemo-
therapy, the addition of radiotherapy can only 
contribute additional toxic effects. Among the 46 
patients requiring second-line therapy, 32% of 
those in the group with no further therapy, 50% 
in the radiotherapy group, and 57% in the group 
with positive PET findings underwent transplan-
tation; this provides reassurance that recurrence 
of Hodgkin’s lymphoma in the group with no 
further therapy was not associated with exces-
sive use of intensive treatment approaches.
On the basis of a maximum allowable differ-
ence of 7 percentage points, this study did not 
show noninferiority of the strategy of no further 
treatment; although the measured difference was 
3.8 percentage points, the 95% confidence interval 
included a possible difference of up to 8.8 per-
centage points. Nevertheless, the results of RAPID 
suggest a rationale for taking a more individual-
ized approach to the treatment of early-stage 
Hodgkin’s lymphoma.
The European Organisation for Research and 
Treatment of Cancer (EORTC) and Lymphoma 
Figure 3. Kaplan–Meier Plot of Overall Survival.
Included are data from patients with negative PET findings who underwent 
randomization and were included in the intention-to-treat analysis (420 pa-
tients).
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Study Association (LYSA) H10 trial29 has also in-
vestigated a PET-based response-adapted approach 
in stage IA and stage IIA Hodgkin’s lymphoma. 
Patients with favorable or unfavorable pretreat-
ment characteristics (the favorable subgroup and 
unfavorable subgroup, respectively) were randomly 
assigned to receive either standard treatment 
(ABVD plus involved-node radiotherapy) or treat-
ment based on PET findings after two cycles of 
ABVD. In the PET-directed group, patients with 
negative PET findings after two cycles of ABVD 
received an additional two (favorable subgroup) or 
four (unfavorable subgroup) cycles, and the pa-
tients with positive PET findings after the initial 
two cycles of ABVD received escalated therapy with 
bleomycin, etoposide, doxorubicin, cyclophospha-
mide, vincristine, procarbazine, and prednisone 
(BEACOPP)30,31 plus radiotherapy. An interim anal-
ysis performed after a median of 1.1 years of 
follow-up showed that in the favorable subgroup 
with negative PET findings, the 1-year progres-
sion-free survival rate was 100.0% in the ABVD 
plus radiotherapy group and 94.9% in the ABVD-
only group (hazard ratio for progression-free 
survival, 9.36; P = 0.026). In the unfavorable sub-
group, the corresponding 1-year progression-free 
survival rates were 97.3% and 94.7% (hazard ra-
tio, 2.42; P = 0.026). On the basis of the statistical 
design, the authors determined that the chemo-
therapy-only treatment for patients with negative 
PET findings should be halted early for futility. 
It can be argued, however, that the H10 and 
RAPID trials show similar results: radiotherapy 
after initial chemotherapy marginally improves 
the progression-free survival rate, as compared 
with chemotherapy alone, but at the expense of 
exposing to radiation all patients with negative 
PET findings, most of whom are already cured.
In stage IA and stage IIA Hodgkin’s lymphoma 
with no mediastinal bulk, patients with negative 
PET findings after three cycles of ABVD have a 
very good prognosis either with or without con-
solidation radiotherapy. Although the noninferi-
ority margin was exceeded in this study, the results 
suggest that radiotherapy can be avoided for pa-
tients with negative PET findings. A longer fol-
low-up period is required to determine whether 
the response-adapted approach used in RAPID 
leads to fewer second cancers, less cardiovascular 
disease, and improved overall survival, as com-
pared with a strategy incorporating radiotherapy 
for all patients.
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